

# Hyunseok Kang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/363123/publications.pdf>

Version: 2024-02-01

69  
papers

5,066  
citations

249298

26  
h-index

139680

61  
g-index

70  
all docs

70  
docs citations

70  
times ranked

8624  
citing authors

#	ARTICLE	IF	CITATIONS
1	Real-World Experience of <i>NTRK</i> Fusion-Positive Thyroid Cancer. <i>JCO Precision Oncology</i> , 2022, 6, e2100442.	1.5	10
2	Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. , 2022, 10, e003026.		38
3	Non-Iodine-Avid Disease Is Highly Prevalent in Distant Metastatic Differentiated Thyroid Cancer With Papillary Histology. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3206-e3216.	1.8	7
4	CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirus-Associated Head and Neck Cancers. <i>Molecular Cancer Research</i> , 2021, 19, 14-24.	1.5	14
5	Treatment of Fanconi Anemia-Associated Head and Neck Cancer: Opportunities to Improve Outcomes. <i>Clinical Cancer Research</i> , 2021, 27, 5168-5187.	3.2	18
6	Molecular Markers that Matter in Salivary Malignancy. <i>Otolaryngologic Clinics of North America</i> , 2021, 54, 613-627.	0.5	2
7	Ovarian Failure Preceding Head and Neck Squamous Cell Carcinoma Identifies an Adult-Onset Cancer-Prone Syndrome Caused by <i>FANCM</i> Mutations. <i>JCO Precision Oncology</i> , 2021, 5, 1443-1448.	1.5	5
8	Newly Identified Members of FGFR1 Splice Variants Engage in Cross-talk with AXL/AKT Axis in Salivary Adenoid Cystic Carcinoma. <i>Cancer Research</i> , 2021, 81, 1001-1013.	0.4	10
9	Effect of chemotherapy and radiotherapy on cognitive impairment in colorectal cancer: evidence from Korean National Health Insurance Database Cohort. <i>Epidemiology and Health</i> , 2021, 43, e2021093.	0.8	4
10	Therapeutic implications of activating noncanonical PIK3CA mutations in head and neck squamous cell carcinoma. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	20
11	What's New in Molecular Targeted Therapies for Thyroid Cancer?. <i>Korean Society for Head and Neck Oncology</i> , 2021, 37, 1-9.	0.1	0
12	The efficacy of anti-PD-1 immune checkpoint inhibitor in nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2020, 108, 104935.	0.8	4
13	Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers. <i>New England Journal of Medicine</i> , 2020, 383, 825-835.	13.9	454
14	Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. <i>Annals of Oncology</i> , 2020, 31, 412-421.	0.6	84
15	Squamous cell carcinoma of head and neck: what internists should know. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 1031-1044.	0.7	19
16	Clinical Benefit to an Aurora A Kinase Inhibitor in a Patient with Metastatic Integrase Interactor 1-Deficient Carcinoma. <i>Oncologist</i> , 2019, 24, 146-150.	1.9	5
17	Genomic Profiling of Parathyroid Carcinoma Reveals Genomic Alterations Suggesting Benefit from Therapy. <i>Oncologist</i> , 2019, 24, 791-797.	1.9	36
18	Short- and long-term outcomes of oropharyngeal cancer care in the elderly. <i>Laryngoscope</i> , 2018, 128, 2084-2093.	1.1	16

#	ARTICLE	IF	CITATIONS
19	Quality indicators of oropharyngeal cancer care in the elderly. <i>Laryngoscope</i> , 2018, 128, 2312-2319.	1.1	3
20	Treatment, survival, and costs of oropharyngeal cancer care in the elderly. <i>Laryngoscope</i> , 2018, 128, 1103-1112.	1.1	6
21	Treatment, short-term outcomes, and costs associated with larynx cancer care in commercially insured patients. <i>Laryngoscope</i> , 2018, 128, 91-101.	1.1	6
22	Response to R-CHOP in HPV-related squamous cell carcinoma of base of tongue: a case report. <i>Cancers of the Head &amp; Neck</i> , 2018, 3, 2.	6.2	4
23	Pattern of planned systemic therapy usage in newly diagnosed, nonmetastatic squamous cell carcinoma of the head and neck in a commercially insured population in the United States. <i>Head and Neck</i> , 2018, 40, 2612-2620.	0.9	1
24	Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas. <i>Head and Neck</i> , 2018, 40, E100-E106.	0.9	23
25	PD-1 Blockade-Induced Pruritus Treated with a Mu-Opioid Receptor Antagonist. <i>New England Journal of Medicine</i> , 2018, 379, 1578-1579.	13.9	24
26	Association between pretreatment lymphocyte count and response to PD1 inhibitors in head and neck squamous cell carcinomas. , 2018, 6, 84.		83
27	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. <i>British Journal of Cancer</i> , 2018, 119, 153-159.	2.9	329
28	Detection of AR-V7 transcript with RNA in situ hybridization in human salivary duct cancer. <i>Oral Oncology</i> , 2018, 84, 134-136.	0.8	4
29	A robust response to combination immune checkpoint inhibitor therapy in HPV-related small cell cancer: a case report. , 2018, 6, 33.		21
30	Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC). <i>Cancers of the Head &amp; Neck</i> , 2018, 3, 3.	6.2	58
31	Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancer. <i>Epidemiology and Health</i> , 2018, 40, e2018040.	0.8	7
32	Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 283-288.	3.2	70
33	Evaluation of proposed staging systems for human papillomavirus-related oropharyngeal squamous cell carcinoma. <i>Cancer</i> , 2017, 123, 1768-1777.	2.0	51
34	SMAD4 Loss Is Associated with Cetuximab Resistance and Induction of MAPK/JNK Activation in Head and Neck Cancer Cells. <i>Clinical Cancer Research</i> , 2017, 23, 5162-5175.	3.2	64
35	Differences in the Prevalence of Human Papillomavirus (HPV) in Head and Neck Squamous Cell Cancers by Sex, Race, Anatomic Tumor Site, and HPV Detection Method. <i>JAMA Oncology</i> , 2017, 3, 169.	3.4	104
36	Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2017, 7, 264-276.	7.7	706

#	ARTICLE	IF	CITATIONS
37	Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy. <i>Oral Oncology</i> , 2017, 74, 40-48.	0.8	74
38	Quality indicators of laryngeal cancer care in commercially insured patients. <i>Laryngoscope</i> , 2017, 127, 2805-2812.	1.1	6
39	The role of human papillomavirus on the prognosis and treatment of oropharyngeal carcinoma. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 449-461.	2.7	37
40	High-resolution microbiome profiling uncovers <i>Fusobacterium nucleatum</i> , <i>Lactobacillus gasseri/johnsonii</i> , and <i>Lactobacillus vaginalis</i> associated to oral and oropharyngeal cancer in saliva from HPV positive and HPV negative patients treated with surgery and chemo-radiation. <i>Oncotarget</i> , 2017, 8, 110931-110948.	0.8	79
41	Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 1542-1549.	0.8	527
42	An open-label, multicohort, phase I/II study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 6025-6025.	0.8	25
43	Comprehensive genomic profiling of parathyroid carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6088-6088.	0.8	1
44	Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. <i>Journal of Clinical Oncology</i> , 2016, 34, 3838-3845.	0.8	715
45	FDG PET/CT in Patients With Head and Neck Squamous Cell Carcinoma After Primary Surgical Resection With or Without Chemoradiation Therapy. <i>American Journal of Roentgenology</i> , 2016, 206, 1093-1100.	1.0	16
46	A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2016, 53, 54-59.	0.8	10
47	Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 6011-6011.	0.8	11
48	Biomarkers in Head and Neck Cancer. , 2016, , 149-162.		0
49	Analysis of chemotherapy selection for locally advanced squamous cell carcinoma of head and neck (SCCHN) in a commercially insured population in the United States.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6066-6066.	0.8	0
50	FDG PET/CT for Management and Assessing Outcomes of Squamous Cell Cancer of the Oral Cavity. <i>American Journal of Roentgenology</i> , 2015, 205, W150-W161.	1.0	31
51	Genomic alterations in head and neck squamous cell carcinoma determined by cancer gene-targeted sequencing. <i>Annals of Oncology</i> , 2015, 26, 1216-1223.	0.6	163
52	Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. <i>Science Translational Medicine</i> , 2015, 7, 293ra104.	5.8	372
53	Intratherapy or Posttherapy FDG PET or FDG PET/CT for Patients With Head and Neck Cancer: A Systematic Review and Meta-analysis of Prognostic Studies. <i>American Journal of Roentgenology</i> , 2015, 205, 1102-1113.	1.0	22
54	Emerging biomarkers in head and neck cancer in the era of genomics. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 11-26.	12.5	264

#	ARTICLE	IF	CITATIONS
55	Class I HDACs Are Mediators of Smoke Carcinogen-Induced Stabilization of DNMT1 and Serve as Promising Targets for Chemoprevention of Lung Cancer. <i>Cancer Prevention Research</i> , 2014, 7, 351-361.	0.7	38
56	FDG PET/CT in the Management of Nasopharyngeal Carcinoma. <i>American Journal of Roentgenology</i> , 2014, 203, W146-W157.	1.0	43
57	A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. <i>Annals of Oncology</i> , 2014, 25, 2230-2236.	0.6	36
58	Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer. <i>Cancer</i> , 2014, 120, 1394-1400.	2.0	27
59	Head and Neck PET/CT: Therapy Response Interpretation Criteria (Hopkins Criteria) Interreader Reliability, Accuracy, and Survival Outcomes. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1411-1416.	2.8	156
60	Antitumor effect of IMG289, an anti-EGFR antibody-drug conjugate (ADC), in preclinical models of head and neck squamous cell carcinomas (HNSCC). <i>Journal of Clinical Oncology</i> , 2014, 32, e17046-e17046.	0.8	3
61	Efficacy and Safety of Dual Calcium Channel Blockade for the Treatment of Hypertension: A Meta-Analysis. <i>American Journal of Hypertension</i> , 2013, 26, 287-297.	1.0	13
62	Abstract 3616: Androgen deprivation therapy and second primary lung cancer risk in prostate cancer patients in the US Veterans. , 2013, , .		0
63	Abstract 4528: Folate receptor targeted iron oxide nanoparticles loaded with cisplatin for imaging and therapy in head and neck squamous cell carcinoma (HNSCC). , 2013, , .		0
64	Chemotherapy in the Treatment of Metastatic Gastric Cancer: Is There a Global Standard?. <i>Current Treatment Options in Oncology</i> , 2011, 12, 96-106.	1.3	28
65	Differential Impacts of Insulin-Like Growth Factor-Binding Protein-3 (IGFBP-3) in Epithelial IGF-Induced Lung Cancer Development. <i>Endocrinology</i> , 2011, 152, 2164-2173.	1.4	20
66	Green Tea Consumption and Stomach Cancer Risk: A Meta-Analysis. <i>Epidemiology and Health</i> , 2010, 32, e2010001.	0.8	34
67	Systolic Blood Pressure and Outcomes in Patients Hospitalized With Acute Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 807.	3.8	1
68	Autologous bone-marrow stem cells for myocardial infarction. <i>Lancet</i> , The, 2006, 368, 27.	6.3	3
69	Granulocyte Colony-Stimulating Factor and Acute Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 1967.	3.8	1